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ABSTRACT: Recently, more studies have aimed at identify-
ing selective peroxisome proliferator-activated receptor gamma
(PPARγ) modulators that transactivate the expression of
PPARγ-dependent genes as partial agonists to improve diabetic
symptoms with fewer side eﬀects compared to classic PPARγ
agonists such as thiazolidinediones. We found that dihydro-
sanguinarine (DHS) treatment induced preadipocyte diﬀer-
entiation and lipid droplet accumulation in 3T3-L1 cells, but
this eﬀect is weaker than that elicited by the full PPARγ agonist
troglitazone. Furthermore, this eﬀect was reduced by the
addition of a PPARγ antagonist, indicating the involvement of
PPARγ signaling. Our results suggest that the stimulatory
eﬀects of DHS on adipocyte diﬀerentiation and insulin sensitivity are mediated by suppressing adenosine monophosphate-
activated protein kinase (AMPK) alpha, upregulating the expression of PPARγ and its target genes (particularly Glut-4 and
adiponectin) and reducing PPARγ phosphorylation. DHS signiﬁcantly enhanced the glucose uptake in 3T3-L1 adipocytes without
observable cytotoxicity at the eﬀective concentration (5 μM) applied.
1. INTRODUCTION
The adipocyte diﬀerentiation process is tightly controlled by
molecular and cellular mechanisms, including transcriptional
factors and extracellular proteins. Many of the genes associated
with the diﬀerentiation and maintenance of the adipocyte
phenotype could be involved in metabolic disorders, such as
type-2 diabetes and obesity.1 Peroxisome proliferator-activated
receptor gamma (PPARγ) is a member of the nuclear receptor
superfamily of ligand-inducible transcription factors and is a
master regulator of adipocyte diﬀerentiation and metabolism,
controlling the gene networks involved in lipid metabolism and
glucose homeostasis.2,3 PPARγ is the ultimate eﬀector of
adipogenesis in a transcriptional cascade that also involves
members of the C/EBP (CCAAT enhancer binding protein)
transcription factor family.4,5 Together, these proteins regulate
downstream target genes involved in adipogenesis.6 Inhibition
of PPARγ activity was reported to exert antiadipogenic eﬀects,
and PPARγ antagonists have been suggested as candidate drugs
for antiobesity.7,8 By contrast, hyperactivation of PPARγ
induced adipose tissue expansion, weight gain, and fatty livers
in human subjects and animals studies as well as adipogenesis in
vitro.2,9 However, activation of PPARγ also yields beneﬁcial
eﬀectsit has been shown to improve glucose homeostasis and
insulin sensitivity.10,11 Full PPARγ agonists such as thiazolidi-
nediones are an eﬀective class of drugs for treating type-2
diabetes. However, they have serious side eﬀects such as weight
gain, bone loss, ﬂuid retention, and cardiac risks, which has led
to their restricted use in patients.12
Recently, more studies have focused on ﬁnding novel
ligandsselective PPARγ modulatorsfrom synthetic and
natural compounds that exhibit partial agonism based on
selective receptor−cofactor interactions and can target gene
regulation. In vivo studies reported that some PPARγ activators
from natural compounds, such as honokiol, amorfrutin 1, and
amorphastilbol, improved metabolic parameters in diabetic
animal models with fewer side eﬀects than full PPARγ agonists
such as thiazolidinediones.13 Many plant alkaloids were
reported to possess potent pharmacological activities and
have been implemented in traditional medicine as well as
considered a model for modern drug synthesis. However, most
of these natural products, especially the benzylisoquinoline
alkaloids (BIAs), remain largely unexplored regarding their
partial PPARγ agonistic activity. Sanguinarine is a benzophe-
nanthridine alkaloid present in the Papaveraceae, Fumariaceae,
and Rutaceae families of plants with reported antimicrobial,
antiinﬂammatory, and antitumor activities.14−16 The pharma-
cokinetic results of sanguinarine in animal studies demonstrated
that its in vivo availability is apparently low and that the main
sanguinarine metabolic pathway is iminium bond reduction,
which results in dihydrosanguinarine (DHS) formation.17
Previously, we found that BIAs exhibited lipid metabolism-
modulating activity in Caenorhabditis elegans. Treatment with
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berberine and sanguinarine reduced lipid droplet accumulation
in the worms. This lipid reduction eﬀect was linked to
adenosine monophosphate-activated protein kinase (AMPK)
activation.18 AMPK signaling lies upstream of the PPARγ
pathway, and AMPK activation can inhibit adipocyte diﬀer-
entiation and modulate energy metabolism-related gene
transcription.19,20
Owing to its potential to diﬀerentiate from ﬁbroblasts to
adipocytes, the 3T3-L1 cell line has been extensively used to
study adipogenesis and the biochemistry of adipocytes.21 Here,
we investigated the adipogenic eﬀect of several BIAs (DHS,
sanguinarine, and berberine) in mouse 3T3-L1 adipocytes.
Quantitative real-time polymerase chain reaction (RT-PCR)
results showed increase of the PPARγ downstream target gene
expressions and adipogenesis markers after DHS treatment.
However, its induction of PPARγ was not as strong as that of
the full agonist, troglitazone. Therefore, we characterized the
activity of DHS associated with the PPARγ, AMPK, and insulin
signaling pathways in comparison with troglitazone. Interest-
ingly, we found that DHS induced adipocyte diﬀerentiation,
whereas its oxidized form, sanguinarine, did not. We also
investigated the metabolic fate and the cytotoxicity of DHS in
3T3-L1 adipocytes.
2. RESULTS AND DISCUSSION
In this study, we investigated the eﬀects of berberine and
sanguinarine on lipid metabolism in mammalian cells. We also
examined the activity of DHS (Figure 1a) because it is the main
metabolite of sanguinarine.17 Preadipocytes (day 0) were
incubated in a diﬀerentiation medium in the presence or
absence of 5 μM alkaloid for 2 days and then replaced with a
fresh medium containing insulin in the presence or absence of
alkaloid every 2 days until day 8. The adipocytes were then
stained with Oil Red O. Among the treated cells, berberine-
treated cells showed reduced lipid droplet accumulation (Figure
1b), and DHS-treated cells showed a higher density of lipid
droplets, but the sanguinarine-treated cells showed no
signiﬁcant change compared to untreated cells. Quantitative
measurements of the cellular triglyceride levels also indicated
similar results to those of the lipid droplet staining. Next, we
treated preadipocytes with troglitazone (a known PPARγ
agonist that induces adipogenesis). Both the results of Oil Red
O staining and the triglyceride measurement showed that DHS
and troglitazone treatments increased lipid droplet accumu-
lation in 3T3-L1 cells. However, DHS exhibited a weaker eﬀect
than troglitazone at the same concentration (Figure 1c). DHS
showed a dose-dependent adipogenic eﬀect from 2 to 10 μM
Figure 1. (a) Molecular structures of dihydrosanguinarine (DHS) and sanguinarine. (b) Oil Red O stain of 3T3-L1 adipocytes and the triglyceride
content in 3T3-L1 adipocytes at day 12 and (c) day 8. All compounds were tested at 5 μM [containing 0.1% dimethyl sulfoxide (DMSO)]. n = 9
from three independent experiments. (d) Triglyceride content in 3T3-L1 adipocytes at day 8 after treatment with various concentrations of DHS. n
= 3; error bar = standard deviation (SD). *p < 0.05, **p < 0.005, ***p < 0.001 vs control; two-tailed Student’s t-test.
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(Figure 1d), whereas high cytotoxicity was observed at
concentrations higher than 10 μM (see below).
The conversion of preadipocytes into adipocytes involves the
activation of key transcription factors such as PPARγ and C/
EBP. During the diﬀerentiation process, increased C/EBPβ and
C/EBPδ activity induces the transcription of C/EBPα and
PPARγ.22 We conducted quantitative RT-PCR to examine the
eﬀect of DHS on the expression proﬁles of genes involved in
adipogenesis in 3T3-L1 cells compared with the eﬀects of the
same concentration (5 μM) of berberine and troglitazone as
well as with the nontreated control.
As shown in Figure 2, the expression of many adipogenesis-
related genes was signiﬁcantly aﬀected. The two main
adipogenic transcription factorsPPARγ and C/EBPαwere
signiﬁcantly upregulated by troglitazone and DHS. Some
PPARγ target genes, including adipocyte-speciﬁc genes, such
as insulin-dependent glucose transporter (Glut4), adipose fatty
acid-binding protein 2 (aP2), cluster of diﬀerentiation 36
Figure 2. Quantitative RT-PCR of adipogenesis-related pathway genes. 3T3-L1 preadipocytes were treated with 5 μM troglitazone (T), berberine
(B), or DHS (D) for 5 days. n = 3 from three independent experiments; error bar = SD. *p < 0.05, **p < 0.005, ***p < 0.001 vs control; two-tailed
Student’s t-test.
Figure 3. (a) Oil Red O staining of 3T3-L1 adipocytes and triglyceride content in 3T3-L1 adipocytes at day 8. n = 3; error bar = SD. *p < 0.05, ***p
< 0.001; acompared to control, bcompared to G10 [analysis of variance (ANOVA) followed by Dunnett’s multiple comparisons test]. (b)
Quantitative RT-PCR of adipogenic genes in 3T3-L1 preadipocytes treated with 5 μM DHS (D5) or 10 μM GW9662 and 5 μM DHS (G10 + D5)
for 5 days. n = 3; error bar = SD. *p < 0.05, **p < 0.005 compared to respective control; two-tailed Student’s t-test. (c) Immunoblotting analyses of
3T3-L1 preadipocytes treated with 5 μM DHS (D5), 10 μM GW9662, and 5 μM DHS (GD), or 5 μM troglitazone (T5) for 5 days. n = 3; error bar
= SD. *p < 0.05, ***p < 0.001; acompared to control, bcompared to D5 (ANOVA followed by Dunnett’s multiple comparisons test).
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(CD36), and adiponectin, were also upregulated, suggesting
that DHS enhances adipocyte diﬀerentiation through the
PPARγ signaling pathway. Similar to the observed increases
in lipid droplet accumulation (Figure 1c), DHS exhibited a
weaker eﬀect than troglitazone at a 5 μM dose. By contrast, 5
μM berberine suppressed the expression of genes involved in
PPARγ signaling as shown by the downregulated PPARγ target
genes. These results are consistent with a report that berberine
inhibits adipocyte diﬀerentiation through the PPARγ path-
way.23,24
PPARγ coactivator 1-alpha (PPARGC1A or PGC-1α) is a
transcriptional coactivator for steroid receptors and nuclear
receptors. It increases the transcriptional activity of PPARγ and
plays an essential role in metabolic reprogramming in response
to dietary availability by coordinating the expression of a wide
array of genes involved in glucose and fatty acid metabolism.25
Antidiabetic drugs such as thiazolidinediones (including
troglitazone and rosiglitazone) increase insulin sensitivity by
acting on the adipose, muscle, and liver to increase glucose
utilization and decrease glucose production. Thiazolidinedione
(rosiglitazone) treatment of obese mice boosts PGC-1α
transcription in the white adipose tissue, which is accompanied
by increased mitochondrial function and insulin sensitivity.26
Our qRT-PCR results showed that the troglitazone treatment
upregulated PPARGC1A expression in 3T3-L1 cells, whereas
the eﬀects of berberine and DHS treatment were marginal.
To investigate whether the eﬀect of DHS is mediated by
PPARγ, we cotreated preadipocytes with DHS (5 μM) and
GW9662 (10 μM), a PPARγ antagonist. Lipid droplet
accumulation and triglyceride levels were signiﬁcantly reduced
in the presence of GW9662 compared to DHS alone (Figure
3a). However, simultaneous treatment with DHS and GW9662
did not completely eliminate the adipogenic eﬀect of DHS on
3T3-L1 cells. This suggests the possibility of an additional
mechanism involved in the adipogenic eﬀect of DHS.
Next, we examined the impact of GW9662-mediated PPARγ
inhibition on the upregulation of adipogenesis-related genes
observed in DHS-treated cells. The qRT-PCR results showed
that cotreatment of DHS with GW9662 suppressed the mRNA
levels of the adipogenic factor C/EBPα and the target genes of
PPARγ, that is, aP2 and CD36. The transcript levels of PPARγ
were reduced in cells treated with addition of GW9662
compared to when treated with DHS alone (Figure 3b).
Furthermore, the immunoblotting results showed that the
PPARγ protein levels were signiﬁcantly reduced in cells
cotreated with DHS and GW9662, whereas the C/EBPα levels
showed a trend of reduced expression (Figure 3c). These
results indicate that the adipogenic eﬀect of DHS is partially
dependent on PPARγ signaling.
Because DHS induced adipogenesis and upregulated PPARγ
and its downstream adipogenic marker gene expressions, we
determine its potential as a ligand for PPARγ using a nuclear
receptor cofactor assay system in comparison to GW1929, a
PPARγ agonist which was supplied with the assay kit as the
reference positive control. The half-maximal eﬀective concen-
tration (EC50) values for DHS and GW1929 are approximately
30 μM and 9 nM, respectively (Figure 4a), whereas the
reported EC50 value for troglitazone is 780 nM.
27 This indicates
that DHS has poor aﬃnity to PPARγ. We also carried out a
PPARγ transactivation assay to evaluate the speciﬁcity and
transactivity of DHS by expressing a GAL4 DNA-binding
domain/PPARγ ligand-binding domain (LBD) chimera protein
using a pGAL4-PPARγ LBD plasmid and a luciferase reporter
plasmid pUAS-tk-Luc containing the target sequence of GAL4
in HepG2 cells. In our luciferase reporter assay, DHS did not
activate PPARγ in the range of 2−10 μM (Figure 4b). The
transactivation assay was repeated using 3T3-L1 cells.
Rosiglitazone and troglitazone showed PPARγ transactivation
with EC50 values approximately 80 and 800 nM, respectively.
The reported EC50 values for these full agonists using the
mouse PPARγ receptor were 60−90 and 780 nM, respec-
tively,27 close to our results (Figure 4c). However, the DHS
treatment showed no transactivation activity relative to the
control (Figures 4c and S1). These results indicate that the
adipogenic eﬀect of DHS is distinct from that of full PPARγ
agonists.
AMPK functions like biological fuel gauge, which is activated
under conditions that deplete cellular adenosine triphosphate
(ATP), and is phosphorylated on the catalytic α-subunit at
Thr172 by the upstream kinase LKB1. It can also be stimulated
by other stimuli that do not cause a detectable change in the
AMP/ATP ratio, including hyperosmotic stress and drugs such
as thiazolidinediones, metformin, and 5-aminoimidazole-4-
carboxamide ribonucleotide.28 AMPK is activated during the
lipolysis process in adipocytes and has been reported to
modulate the transcription of many genes involved in energy
metabolism, including lipogenesis, triglyceride synthesis, and
fatty acid oxidation.29 Studies have reported that the lipid-
reducing eﬀect of natural products acts via AMPK activation.
These phytochemicals include polyphenols such as resveratrol,
Figure 4. (a) Binding ability of DHS to PPAR in a nuclear receptor cofactor assay. GW1929 was used as a positive control. This experiment was
performed in duplicate, and the average values are shown. (b) Transactivation activity of the PPARγ-derived reporter gene in HepG2 cells after
treatment with troglitazone (T) and DHS (D) in μM. Relative luciferase activities were normalized to β-galactosidase activity. n = 3; error bar = SD.
**p < 0.01 vs control, two-tailed Student’s t-test. (c) PPARγ transactivation activity in 3T3-L1 cells. The average values were shown (n = 3). The
results were normalized to control (0.1% DMSO).
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ginsenoside, and epigallocatechin gallate as well as plant
alkaloids such as berberine and sanguinarine.18,30
AMPKα regulates preadipocyte diﬀerentiation by providing
an upstream signal for PPARγ that inhibits adipocyte
diﬀerentiation.19,20 We investigated the involvement of the
AMPK pathway, which lies upstream of PPARγ and C/EBPα,
in the adipogenic eﬀect of DHS. The immunoblotting results
showed that DHS signiﬁcantly reduced the AMPKα levels at 5
μM but not at 10 μM (Figure 5a). The eﬀect of 5 μM
troglitazone on AMPKα levels was also insigniﬁcant (Figure
5b). Although the mechanism of how certain plant natural
products activate AMPK signaling while others suppress this
signaling pathway is still unknown, our result implies that the
DHS treatment stimulates adipocyte diﬀerentiation via
upregulation of PPARγ by inhibiting AMPKα-mediated signal-
ing.
Studies have found that PPARγ is also regulated by
posttranslational modiﬁcation, resulting in insulin sensitization
independent of transactivation. Phosphorylation of PPARγ at
Ser273 by cyclin-dependent kinase 5 (CDK5) is linked to
obesity. Agonists and antagonists of PPARγ have been shown
to exert their insulin-sensitizing eﬀects by blocking CDK5/ERK
phosphorylation. PPARγ agonists with antidiabetic eﬀects such
as thiazolidinediones were found to inhibit CDK5-mediated
PPARγ phosphorylation in the adipose tissue.31 Several PPARγ
ligands with weak agonistic activity exhibited strong antidiabetic
eﬀects in vivo. Those ligands were shown to inhibit CDK5-
mediated PPARγ phosphorylation. As such, the ability of a
ligand to suppress PPARγ Ser273 phosphorylation was
correlated with its antidiabetic eﬀect but independent of its
agonistic activity.32 Therefore, targeted inhibition of PPARγ
Ser273 phosphorylation was suggested for developing new
classes of antidiabetic drugs.
Here, we investigated the eﬀect of DHS on PPARγ Ser273
phosphorylation in comparison to troglitazone and berberine at
day 5. The immunoblotting results showed that DHS increased
PPARγ protein expression of the treated cells, but the overall
PPARγ phosphorylation was signiﬁcantly decreased (Figure
6a). The reduction of the PPARγ phosphorylation level by
DHS was more apparent after 24 h treatment than at day 5,
most possibly because of the in vivo metabolism of DHS over
time. At 5 μM, DHS signiﬁcantly reduced AMPKα and PPARγ
phosphorylation levels. Treatment with 10 μM DHS had no
eﬀect on AMPKα and showed weaker reduction of PPARγ
phosphorylation than with 5 μM DHS (Figures 6b and 5a).
These results suggest that DHS acts via PPARγ- and AMPKα-
mediated signaling, and the eﬀects are dose-dependent. The
decrease of PPARγ phosphorylation suggested the potential of
DHS as an antidiabetic agent; therefore, we next performed a
glucose uptake assay to evaluate this eﬀect.
In the adipose tissue, PPARγ induces the expression of genes
involved in glucose uptake and controls adipocyte-secreted
factors such as adiponectin to aﬀect whole-body insulin
sensitivity. Adiponectin has been shown to play an important
role in mediating glucose uptake in adipocytes and muscle cells.
Recent genome-wide scans have mapped a susceptibility locus
for type-2 diabetes and metabolic syndrome to chromosome
3q27, where the gene-encoding adiponectin is located.33
Decreased adiponectin expression was correlated with insulin
Figure 5. Immunoblotting analyses of 3T3-L1 preadipocytes treated
with (a) 2, 5, or 10 μM DHS for 24 h; (b) 5 μM troglitazone or 5 μM
DHS for 5 days. DDHS, Ttroglitazone. n = 6, error bar = SD. *p
< 0.05 vs control; two-tailed Student’s t-test.
Figure 6. Immunoblotting analyses of 3T3-L1 preadipocytes treated
with (a) 5 μM troglitazone (T), berberine (B), or DHS (D) for 5 days.
(b) 2, 5, or 10 μM DHS for 24 h. n = 3 from three independent
experiments; error bar = SD. *p < 0.05 vs control; two-tailed Student’s
t-test. (c) Glucose uptake eﬀect of troglitazone (T), berberine (B), and
DHS (D). Adipocytes were treated with 5 μM troglitazone, 5 μM
berberine, or 5 or 10 μM DHS. The values are normalized to the
protein content of each sample. n = 3 from three independent
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resistance in mouse models of altered insulin sensitivity and in
type-2 diabetes subjects.34
In mammalian cells, facilitative diﬀusion of glucose across the
plasma membrane is mediated by a family of glucose
transporters.35 GLUT4 is a glucose transporter isoform,
which is only expressed in peripheral tissues that are targets
for insulin action, that is, the adipose tissue, cardiac muscle, and
skeletal muscle. When stimulated by insulin, GLUT4 trans-
locates from its intracellular compartment to the plasma
membrane and, therefore, is responsible for insulin-stimulated
glucose uptake.36
To evaluate whether DHS enhances glucose uptake, we used
an enzymatic method to measure 2-deoxyglucose (2DG)
uptake in diﬀerentiated 3T3-L1 adipocytes. Our results (Figure
6c) showed a signiﬁcant stimulatory eﬀect of insulin-dependent
glucose uptake by DHS in a dose-dependent manner (5 and 10
μM). The berberine treatment also signiﬁcantly increased
glucose uptake in the adipocytes, whereas the troglitazone
treatment only showed a trend of increased glucose uptake.
Berberine has been reported to increase glucose uptake possibly
through a mechanism other than PPARγ activation, as this
compound showed antagonistic activity. The expression and
cellular localization of GLUT4 were not altered by berberine;
instead, it was suggested to stimulate glucose uptake in 3T3-L1
adipocytes and preadipocytes by increasing GLUT1 activity.37
These results indicate that the eﬀects of DHS and berberine on
glucose uptake act through distinct mechanisms. Future studies
should elucidate the involvement of GLUT1 and GLUT4 plant
alkaloid-mediated glucose uptake. It is worth noting that while
both DHS and troglitazone treatment strongly upregulated
Glut-4 gene expression, induction of the proadipogenic gene
adiponectin by DHS was less pronounced (Figure 2). This
suggests that DHS promotes glucose uptake but exhibits
weaker adipogenicity compared to troglitazone, a thiazolidine-
dione for treating type-2 diabetes.
In drug development, ﬁndings from many studies proposed
that the ligand occupancy time on the receptor would improve
the potency of PPARγ modulators by creating an extended
period of protection against kinase activity, that is, longer
residence times of a drug occupying a target result in improved
duration of action times for that drug.38
Here, we investigated the metabolic fate of DHS and
sanguinarine in 3T3-L1 cells by measuring their accumulation
in vivo and in the culture medium after 48 h using both
alkaloids as standards. A total of 5.7 μmol/g protein of DHS
and 0.1 μmol/g protein of sanguinarine were detected in the
DHS-treated cell extract, whereas 2.7 μmol/g protein of DHS
and 0.3 μmol/g protein of sanguinarine were detected in the
sanguinarine-treated cell extract. In the cell culture medium, 0.1
μM each of DHS and sanguinarine were detected in the DHS-
treated sample, whereas 0.1 μM DHS and 0.3 μM sanguinarine
were detected in the sanguinarine-treated sample. This
indicates high accumulation of DHS in both the cell extract
samples, whereas sanguinarine, the oxidized form, was prevalent
in the culture medium (Figure 7a). This result correlates with
those reported in vivo pharmacokinetic studies that the main
sanguinarine metabolism pathway is the reduction of its
iminium bond to form DHS.16 It also indicates that DHS has
higher accumulation in vivo than sanguinarine and may yield
high bioavailability. The cells treated with 10 μM DHS showed
an insigniﬁcant reduction of the AMPKα level and weaker
eﬀects on the reduction of the PPARγ phosphorylation level
and on adipogenesis compared to 5 μM DHS. Toxicity was also
observed with the 10 μM treatment on the 3T3-L1 cells. These
ﬁndings led us to infer that with 10 μM DHS, the cells
accumulated a higher amount of sanguinarine than the cells
with the 5 μM treatment. As described in our previous work,18
sanguinarine exerts an antiadipogenic eﬀect, activates AMPK,
and thus elicits an opposing eﬀect to DHS.
The observed diﬀerent eﬀects of sanguinarine and DHS on
the adipogenesis of 3T3-L1 cells suggest that the metabolic
pathway of a bioactive compound dictates the ultimate
biological eﬀects in vivo. In our previous study, the
sanguinarine treatment activated the AMPK pathway, which
led to the inhibition of lipid synthesis in C. elegans.18 Although
the mechanism of how sanguinarine activated AMPK signaling
is still not fully elucidated, other studies suggested that this
activity was due to the inhibition of mitochondrial respiratory
complex I, which resulted in an increase of the AMP/ATP ratio.
Sanguinarine has also been reported to activate the
mitochondrial apoptosis pathway.39 We found that the
sanguinarine treatment exhibited toxicity in C. elegans.18
Evaluation of 3T3-L1 cell viability showed that the
cytotoxicity of DHS was insigniﬁcant at 5 μM (Figure 7b).
This suggests that the cytotoxicity of a compound could
contribute to lipid metabolism because of its eﬀect on AMPK
pathway activation. Thus, it would be interesting to investigate
the eﬀect of bioactive compounds and their metabolites on the
multiple signaling pathways involved in adipogenesis and
Figure 7. (a) Accumulation of DHS and sanguinarine in cells and in
the cell culture medium after 48 h treatment with the respective
compound. n = 3 from two independent experiments; error bar = SD.
(b) 3T3-L1 adipocyte viability after 24 h treatment with DHS at
various concentrations. n = 5 from three independent experiments;
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glucose metabolism to elucidate their possible mechanisms of
action and evaluate their potential antiobesity and/or
antidiabetic eﬀects.
In terms of diﬀerences in the molecular structure, the
absence of a positive charge and the nonplanarity due to lack of
conjugation in DHS was reported to be linked with decreased
biological activity compared to sanguinarine.40 However, those
studies only evaluated the toxicological eﬀect of DHS such as
inhibition of protein kinase C and cytotoxicity in cancer cells,
whereby it was found that sanguinarine was more cytotoxic
than DHS. For instance, in the human leukemia HL-60 cell
line, the half-maximal inhibitory concentration, IC50 values of
sanguinarine and DHS were reported as 0.72 and 20 μM,
respectively.41 The in vivo toxicity of sanguinarine was reported
as 2.7 mg/kg body weight in mice, whereas no toxic response
was found in rats fed with DHS up to a dose of 58 mg/kg body
weight per day.42,43 Our ﬁnding that DHS has low cytotoxicity
makes this compound a potential candidate for therapeutic
application.
3. CONCLUSIONS
This is the ﬁrst report that evaluated the eﬀect of DHS, a
reduced form of sanguinarine, on adipogenesis in 3T3-L1 cells.
DHS exhibited a weaker adipogenic eﬀect than the full PPARγ
agonist, troglitazone. Our results suggest that DHS induced
adipocyte diﬀerentiation by upregulating PPARγ and suppress-
ing AMPK signaling pathways. DHS treatment reduced PPARγ
Ser273 phosphorylation and upregulated the expressions of
Glut-4 and adiponectin genesactivities that are associated with
improved insulin sensitivity. We found that 5 μM DHS
signiﬁcantly enhanced glucose uptake in 3T3-L1 adipocytes
without exerting cytotoxicity. Further experiments using animal
models are needed to evaluate the eﬃcacy and safety of DHS
for medical application. Although the interaction of DHS with
PPARγ is not fully elucidated, our results show that DHS
bound weakly with PPARγ and did not transactivate it.
Crystallographic structures of the PPARγ ligand binding
revealed two binding modes exist in the same LBD that
correspond to potent and weak agonists and aﬀect their
transactivation activities. A weak agonist could have low
transactivation activity but high phosphorylation inhibition
activity on PPARγ Ser273, similar to the characteristics of DHS
discovered in this study.44−46 By examining the metabolic fates
of DHS and its oxidized form, sanguinarine, in 3T3-L1 cells, we
discovered the signiﬁcance of considering the metabolites of a
compound during bioactivity screening. This is because the
metabolic pathway of a bioactive compound ultimately dictates
the biological eﬀect in vivo. Our ﬁndings in this study suggest
that BIAs could be potential lead compounds for modulators of
glucose metabolism, and additional screening of these alkaloids
should be carried out in the future.
4. EXPERIMENTAL SECTION
4.1. Chemicals. Berberine sulfate was purchased from
Tokyo Chemical Industry Co., Ltd. (Tokyo, Japan);
troglitazone and GW9662 from Wako Pure Chemical
Industries, Ltd. (Osaka, Japan); and sanguinarine chloride
and rosiglitazone from Sigma-Aldrich (St. Louis, MO, U.S.A.).
DHS was prepared by reducing sanguinarine with NaBH4
reduction.47 The purity was analyzed by LC−MS (see below
and Figure S2). Alkaloid samples are diluted in DMSO (Wako)
to a ﬁnal concentration of 0.1% DMSO in cell treatments. All
other chemicals were purchased from Wako, unless otherwise
stated.
4.2. Purity Check. The purities of dihydrosanguinarine and
sanguinarine were analyzed by an LCMS2010 system
(Shimadzu, Japan) using a TSK-gel ODS-80Tm 4.6 × 250
mm column. The samples were analyzed under the following
conditions: a column temperature of 40 °C; a ﬂow rate of 0.5
mL/min; and a gradient schedule of 0−15 min of AcCN/H2O
= 45:55, 18.5−24.5 min of AcCN/H2O = 80:20, and 28−33
min AcCN/H2O = 45:55 (containing 1% triﬂuoroacetic acid)
in positive SIM-SCAN mode ranging from m/z 100−500. The
purities were calculated based on % peak area for each sample.
4.3. Cell Culture. 3T3-L1 cells (a generous gift from Dr. M.
Nagao, Kyoto University) were cultured at 37 °C, 5% CO2 in
Dulbecco’s modiﬁed Eagle medium (DMEM; Wako) with 10%
fetal bovine serum (FBS; Corning). Cells were passaged twice
before used in assays to allow cells to re-establish the normal
cell cycle. Cell diﬀerentiation was induced at 2 day
postconﬂuence (designated as day 0) by addition of the 3-
isobutyl-1-methylxanthine (IBMX) mix which consists of 5 μg/
mL insulin (Sigma), 500 μM isobutylmethylxanthine (Sigma),
and 0.25 μM dexamethasone for 2 days.48 The culture medium
was replaced every 2 days thereafter with DMEM containing
10% FBS and 5 μg/mL insulin.
4.4. Oil Red O Staining. 3T3-L1 adipocytes (day 8 or day
12) in the wells of cell culture plates were rinsed with
phosphate-buﬀered saline (PBS) and then ﬁxed in formalin for
30 min at room temperature. The formalin was removed, and
the cells were rinsed twice with PBS. A 0.3 w/v % Oil Red O
(Sigma) solution was added at room temperature to stain the
cells. After 1 h, cells were rinsed with PBS twice, and lipid
droplet accumulation was observed under a microscope.
4.5. Triglyceride and Protein Measurement. 3T3-L1
adipocytes (day 12) in the wells of cell culture plates were
rinsed twice with PBS. Cell lysis buﬀer (1 M Tris-HCl pH7.5, 1
M MgCl2, 10% Triton X100) was added to each well, and the
cells were harvested using a cell scraper into Eppendorf tubes.
The cells were disrupted using an ultrasonicator. Triglyceride
and protein contents of the cell lysates were measured. The
triglyceride concentration was determined using triglyceride E
test kit (Wako) and the absorbance at 595 nm was measured
using a PowerScan4 plate reader (DS Pharma Biomedical,
Japan). Protein concentrations were determined using Bio-Rad
DC protein assay (Bio-Rad Laboratories, U.S.A.) reagents and
the absorbance at 595 nm was measured using the PowerScan4
plate reader. The triglyceride content of each cell sample was
normalized to its corresponding protein content.
4.6. Quantitative RT-PCR. Two day postconﬂuent 3T3-L1
cells (day 0) were cultured in the diﬀerentiation medium IBMX
without or with the addition of alkaloids for 2 days, followed by
medium change to DMEM/10% FBS/5 μg/mL insulin without
or with the addition of alkaloids. The cells were harvested on
day 5 following the method for protein as described above.
RNAs were extracted using RNeasy Mini Kit (QIAGEN).
Reverse transcription was done using 2 μg of total RNA, and
RT-PCR was carried out using a CFX96 RT-PCR System (Bio-
Rad Laboratories, Inc., Foster City, CA, U.S.A.). The
conditions for PCR reactions were 95 °C for 15 min, followed
by 40 cycles of 95 °C for 10 s, 60 °C for 20 s, and 72 °C for 20
s. Melting curve analysis was performed after each run at 72
−95 °C to check the speciﬁcity of ampliﬁcation. Data analysis
was done using the ΔΔCT method, and a relative transcript
amount was standardized using the TATA box-binding protein
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as the internal control. Fold changes between samples were
normalized to control (0.1% DMSO).
4.7. Immunoblot Analysis. 3T3-L1 cells were rinsed twice
with PBS. Cell lysis buﬀer (50 mM Tris-HCl pH 7.4, 150 mM
NaCl, 1 mM ethylenediaminetetraacetic acid, 1% Triton X100,
0.1% sodium dodecyl sulfate (SDS), 10 mM NaF, 1 mM
Na3VO4, 50 mM Na4P2O7, and 1% protease inhibitor cocktail)
was added to each well, and the cells were harvested using a cell
scraper into Eppendorf tubes. The cells were disrupted using
the ultrasonicator. Protein contents of cell lysate samples were
measured as mentioned above and adjusted to the same
amount using a 2× sample buﬀer (0.1 M Tris-HCl pH 6.8, 2%
SDS, 12% β-mercaptoethanol, 20% glycerol, and 0.2%
bromophenol blue). The protein (20 μg) was loaded and
separated by SDS-polyacrylamide gel electrophoresis. The
proteins were electro-transferred onto a polyvinylidene
diﬂuoride membrane (Millipore Immobilon-P). The mem-
branes were blocked for 1 h at room temperature in 5% bovine
serum albumin (BSA)/Tris buﬀered saline with Tween-20
(TBST) and then probed with primary antibody (in 5% BSA/
TBST) overnight at 4 °C, followed by horseradish peroxide
(HRP)-conjugated secondary donkey antirabbit IgG (in 5%
BSA/TBST). Target-speciﬁc antibodies were obtained from the
following manufacturers: AMPKα, C/EBPα, PPARγ, and β-
actin from Cell Signaling Technology (Beverly, MA, U.S.A.);
phosphospeciﬁc PPARγ (Ser273) from Funakoshi Co., Ltd.
(Japan); and HRP-conjugated donkey antirabbit IgG from GE
Healthcare (Buckinghamshire, U.K.). Chemiluminescence was
detected using a ChemiDoc Touch imaging system (Bio-Rad
Laboratories, Inc., U.S.A.). The blots were then stripped and
reprobed with other primary antibodies and subjected to
chemiluminescence detection. The target protein band
intensity was quantiﬁed using ImageJ software (NIH). The
average values were normalized to control.
4.8. PPARγ Binding Assay. The ability of DHS to bind
PPARγ was determined using the EnBio receptor cofactor assay
system for PPARγ Kit (EnBio Tec. Laboratories Co., Ltd.,
Tokyo, Japan) following the manufacturer’s protocol. This
system employs a cell-free assay using nuclear receptors and
cofactors to screen for chemicals. Changes in the absorbance at
450 nm for reactions treated with DHS, and the PPARγ agonist
GW1929 (positive control) were measured using the Power-
Scan4 plate reader. The EC50 values were determined from the
concentration that elicited a half-maximal response concen-
tration on the plotted graphs.
4.9. PPARγ Reporter Assay. The assay was performed as
previously described.49 A DNA fragment encoding the LBD
(residues 204−505) of mouse PPARγ2 (GenBank U09138)
with BamHI and SalI sites at the ends was ampliﬁed by PCR
using genomic DNA from mouse 3T3-L1 cells as a template
and inserted into the pSG424 plasmid at the BamHI and SalI
sites to construct pGal4-PPARγ LBD. pGal4-PPARγ LBD and
pUAS-tk-luc were cotransfected into HepG2 or 3T3-L1 cells in
separate experiments using HilyMax (Dojindo). The PPARγ
agonist activity was determined via luciferase activity using a
Luciferase Assay System according to the manufacturer’s
protocol (Promega). The β-galactosidase activity was deter-
mined using chlorophenol red-β-D-galactopyranoside (Roche).
Relative luciferase activities were normalized to the β-
galactosidase activity.
4.10. Glucose Uptake Assay. The assay was performed
according to the reported method50 with modiﬁcations. The
3T3-L1 cells were diﬀerentiated in six-well culture plates. Test
compounds were added to diﬀerentiated adipocytes on day 8.
Insulin stimulation and glucose uptake were conducted on day
12. Cells were lysed with 10 mM Tris-HCl buﬀer (pH 8.0) and
disrupted using the ultrasonicator. Glucose uptake was
determined by 2-deoxyglucose uptake with an enzymatic
photometric assay using 2-deoxyglucose uptake measurement
kit (Cosmo Bio Co., Ltd., Japan). Measurements were done
using the PowerScan4 plate reader at an absorbance of 420 nm
in a kinetic program with a read every 1 min for 30 min.
Glucose uptake values were then normalized to the protein
value of the cell lysates as determined by the Bio-Rad DC
Protein Assay method described above. The insulin-induced
glucose uptake was calculated by subtracting the values from
the negative control (glucose uptake inhibitor added).
4.11. Alkaloid Accumulation Analysis. 3T3-L1 adipo-
cytes (day 4) were treated without or with alkaloids for 48 h
and collected as in protein samples. Cell lysis samples and cell
culture media were extracted with methanol using Sep Pak C18
cartridges (Millipore). Methanol extracts were concentrated
using a rotary evaporator. The samples were analyzed using an
LCMS2020 system (Shimadzu) according to the previously
reported method.23 Alkaloid concentrations were calculated
based on the LC peak area relative to the standard peak area,
and those values are normalized to the protein content in each
sample.
4.12. Cytotoxicity Assay. The 3T3-L1 cells were cultured
at a density of 1.5 × 103 cells/well in a 96-well plate for 16 h.
The culture medium was then replaced with a fresh medium
with the addition of alkaloids and further cultured for 24 h. Cell
viability was determined using Cell Counting Kit-8 (Dojindo).
Cells were incubated with the reagent for 2 h and live cells were
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